Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
100%
Chemotherapy
71%
Neoplasm
69%
Colorectal Carcinoma
49%
Circulating Tumor DNA
36%
Progression Free Survival
36%
Colon Carcinoma
35%
Bevacizumab
34%
Oxaliplatin
33%
Biological Marker
31%
microRNA 126
31%
Overall Survival
30%
microRNA
26%
Rectum Cancer
24%
Capecitabine
20%
Epidermal Growth Factor
19%
Lung Cancer
16%
Metastasis
15%
Biliary Tract Cancer
14%
Malignant Neoplasm
12%
Gamma Interferon
12%
Recurrent Disease
10%
Prostate Cancer
10%
Disease
10%
Primary Tumor
10%
Programmed Death 1 Ligand 1
9%
Disseminated Cancer
9%
Panitumumab
9%
Pembrolizumab
9%
Neuropeptide Y
8%
Vasculotropin A
8%
Clinical Trial
8%
First-Line Chemotherapy
7%
Combination Therapy
7%
Angiogenesis Inhibitor
7%
Gemcitabine
6%
Prospective Study
6%
Epidermal Growth Factor Receptor
6%
Circulating microRNA
6%
Phase II Trials
5%
Non Small Cell Lung Cancer
5%
Immunotherapy
5%
Placebo
5%
Medicine and Dentistry
Neoplasm
75%
Colon Carcinoma
73%
Colorectal Carcinoma
55%
Rectum Cancer
34%
Metastatic Colorectal Cancer
34%
Biological Marker
29%
Malignant Neoplasm
27%
Circulating Tumor DNA
26%
Lung Cancer
24%
Chemotherapy
22%
Overall Survival
20%
Systematic Review
20%
microRNA
18%
Oxaliplatin
17%
microRNA 21
16%
Meta-Analysis
15%
Recurrent Disease
15%
Disease
15%
Biliary Tract Cancer
14%
Stroma
14%
Bevacizumab
14%
DNA Mismatch Repair
14%
Angiogenesis
13%
Progression Free Survival
12%
Capecitabine
12%
Biopsy Technique
11%
microRNA 126
11%
Patient-Reported Outcome
10%
Lung
10%
Diagnosis
10%
Quality of Life
10%
Arm
10%
Chemoradiotherapy
10%
Tumor Infiltrating Lymphocyte
9%
Prostate Cancer
9%
Exon
9%
Drug Megadose
9%
Panitumumab
9%
Pembrolizumab
9%
Lung Tumor
9%
Stereotactic Body Radiation Therapy
9%
Treatment Response
9%
Metastatic Carcinoma
9%
Oncology
9%
Combination Chemotherapy
8%
Adjuvant Therapy
8%
Cancer Diagnosis
8%
Specific Tumor
8%
Cell-Free DNA
8%
Immunotherapy
8%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
42%
Colon
41%
Overall Survival
39%
MicroRNA
36%
Mir-126
29%
Blood Plasma
27%
Natural Killer Cell
24%
Single-Nucleotide Polymorphism
21%
Progression Free Survival
21%
Bevacizumab
19%
Capecitabine
16%
Vascular Endothelial Growth Factor A
16%
Epidermal Growth Factor
14%
Growth Factor-Like Domain
14%
HOXA9
14%
Medline
12%
DNA Methylation
12%
Recurrence Free Survival
11%
Interferon Gamma
11%
Methylation
11%
Embase
10%
Kinase Insert Domain Receptor
10%
Prevalence
10%
Disease Free Survival
10%
Dynamics
9%
Homeobox
9%
Decision Making
9%
Electronic Health Record
9%
Droplet Digital Polymerase Chain Reaction
9%
Microsatellite Instability
8%
Genetics
8%
Cell Activity
8%
Web of Science
8%
Real-Time Polymerase Chain Reaction
8%
Clinical Trial
7%
KRAS
7%
Cohort Study
6%
Eosin
6%
Cancer Cell
6%
Angiogenesis
6%
Computer Assisted Tomography
5%
Cochrane Library
5%
Enzyme
5%
Gene Expression Profiling
5%
Liquid
5%
Vascular Endothelial Growth Factor
5%
Microsatellite
5%
Epidermal Growth Factor Receptor
5%
Somatic Mutation
5%